Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 100,000 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 100,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $983,271.96. This trade represents a 78.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Stock Up 7.7 %

HIMS stock traded up $3.01 during midday trading on Tuesday, reaching $41.94. 16,419,084 shares of the company’s stock traded hands, compared to its average volume of 11,104,599. The firm’s fifty day moving average price is $29.35 and its 200-day moving average price is $22.70. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $41.98. The company has a market cap of $9.16 billion, a price-to-earnings ratio of 95.32 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) earnings per share. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HIMS. Piper Sandler raised their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target on the stock. Finally, Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $25.13.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. Stonekeep Investments LLC increased its stake in Hims & Hers Health by 5.5% in the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after buying an additional 882 shares during the last quarter. Principal Securities Inc. increased its stake in Hims & Hers Health by 48.2% in the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after buying an additional 1,002 shares during the last quarter. CWM LLC lifted its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Cadent Capital Advisors LLC boosted its stake in shares of Hims & Hers Health by 1.5% in the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after buying an additional 1,060 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.